Processes for preparing oxathiazin-like compounds
Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.
1. A method of reducing or inhibiting cancer cell migration in a subject having a pancreatic cancer, an ovarian cancer, or a squamous cell carcinoma comprising administering an effective amount of a compound of formula I
wherein R is H, an alkyl, or benzyl, to the subject.
2. The method of claim 1 , wherein the compound is administered orally, intravenously, topically, or a combination thereof.
3. The method of claim 1 , wherein the compound is
4. The method of claim 1 , comprising administering 0.1 g to about 100 g of the compound per day.
5. The method of claim 1 , comprising administering 5 g to about 30 g of the compound per day.
6. The method of claim 1 , comprising administering the compound in a gel, capsule, tablet, or solution.
7. The method of claim 1 , comprising administering the compound in a pharmaceutical composition at a concentration of about 0.01 to about 3 % w/v.
8. The method of claim 1 , comprising administering the compound in a pharmaceutical composition at a concentration of about 0.01 μg/ml to about 1000 μg/ml.
9. The method of claim 1 , comprising administering the compound in a pharmaceutical composition containing about 0.01 to about 3% taurolidine and/or taurultam.
10. The method of claim 1 , comprising administering the compound orally to the subject.
11. A method of treating a subject having a squamous cell carcinoma, an ovarian cancer, or a pancreatic cancer comprising orally, intravenously, or topically administering 0.1 g to about 100 g of a compound of formula I
wherein R is H, an alkyl, or benzyl, to the subject.
12. The method of claim 11 , wherein the squamous cell carcinoma is a cutaneous squamous cell carcinoma.
13. The method of claim 11 , wherein the compound is administered orally, intravenously, topically, or a combination thereof.
14. The method of claim 11 , wherein the compound is
15. The method of claim 11 , comprising administering 0.1 g to about 100 g of the compound per day.
16. The method of claim 11 , comprising administering 5 g to about 30 g of the compound per day.
17. The method of claim 11 , comprising administering the compound in a gel, capsule, tablet, or solution.
18. The method of claim 11 , comprising administering the compound in a pharmaceutical composition at a concentration of about 0.01 to about 3% w/v.
19. The method of claim 11 , comprising administering the compound in a pharmaceutical composition at a concentration of about 0.01 μg/ml to about 1000 μg/ml.
20. The method of claim 11 , comprising administering the compound in a pharmaceutical composition containing about 0.01 to about 3% taurolidine and/or taurultam.